BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, June 6, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 13, 2019
View Archived Issues
Improbability research yields path to HIV vaccine
Read More
Manageable safety and activity seen with GDC-0077 combination treatments in phase Ib study
Read More
Phase I data presented for the novel M1 mAChR modulator VU-319
Read More
TDP-43-mediated splicing repression as a therapeutic target for ALS-FTD
Read More
EGFL7 as a new therapeutic target in AML
Read More
Phase Ib data for carfilzomib plus chemotherapy in children with refractory ALL
Read More
Positive interim safety data presented from ongoing phase Ib/IIa study of ATYR-1923
Read More
Prescient presents promising interim phase Ib data for PTX-200 in ovarian cancer
Read More
Soligenix initiates phase Ic study of RiVax
Read More
Kaleido to advance KB-174 for HE based on topline data from study in patients with cirrhosis
Read More
First phase III data for YF-H-2015005 shows rapid mobilization of CD34+ cells
Read More
New long-acting HIV-1 fusion inhibitor-based regimen developed
Read More
DPP8 may be a target for multiple myeloma therapy by inducing apoptotic cell death
Read More
Antabio SAS patents new antibacterial compounds
Read More
Adlai Nortye divulges new CSF1R inhibitors
Read More
Innovent Biologics presents PI3K inhibitors
Read More
DYRK2 is a critical checkpoint in the control of leukemia stem cell maintenance
Read More
Merck & Co. describes new IDO1 inhibitors
Read More
Study confirms target engagement with BTRX-335140 in healthy volunteers
Read More
C&C Research Laboratories identifies STAT3 inhibitors
Read More
OrphoMed begins phase II study of ORP-101 in IBS-D
Read More
New phase II trial investigates CFZ-533 in pediatric and young adults with type 1 diabetes
Read More
Phase III study of Tecentriq with Cotellic and Zelboraf in melanoma meets primary endpoint
Read More
Phase II study of TG-4010 combination regimen in advanced NSCLC fails to meet primary endpoint
Read More
FDA grants accelerated approval to Vyondys 53 for DMD in patients amenable to skipping exon 53
Read More
